Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R.sup.1, R.sup.2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment, comprising inhibiting aminolevulinic acid synthase 2 (ALAS2) in the subject by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Disorders that are of particular interest are blood disorders, such as porphyria and anemia.

##STR00001##

A method of making a pyrazole compound includes mixing a diazonium salt with a reactant in the presence of a solvent, thereby coupling a diazo group of the diazonium salt to an ?-carbon atom of the reactant to form a reaction intermediate having a formula of (I) or (II); mixing the reaction intermediate and hydrazine in the presence of a superparamagnetic iron oxide nanoparticles catalyst thereby cyclizing the hydrazine with an ester group of the reaction intermediate to form the pyrazole compound having a formula of (III) or (IV).

##STR00001##

A method of making a pyrazole compound includes mixing a diazonium salt with a reactant in the presence of a solvent, thereby coupling a diazo group of the diazonium salt to an ?-carbon atom of the reactant to form a reaction intermediate having a formula of (I) or (II); mixing the reaction intermediate and hydrazine in the presence of a superparamagnetic iron oxide nanoparticles catalyst thereby cyclizing the hydrazine with an ester group of the reaction intermediate to form the pyrazole compound having a formula of (III) or (IV).

##STR00001##

Triazabutadiene molecules for use in applications. e.g., those involving fluorogenic molecules, e.g., triazabutadiene molecules configured to generate a fluorescent compound when combined with a second molecule, e.g., upon reaction with a tyrosine molecule or other appropriate molecule; and protected triazabutadiene molecules that are stable in acidic conditions and are adapted to release an active (e.g., acid-labile} triazabutadiene molecule upon appropriate conditions, and methods for producing and using said protected or releasable triazabutadiene molecules (and products of cleavage).

Triazabutadiene molecules for use in applications. e.g., those involving fluorogenic molecules, e.g., triazabutadiene molecules configured to generate a fluorescent compound when combined with a second molecule, e.g., upon reaction with a tyrosine molecule or other appropriate molecule; and protected triazabutadiene molecules that are stable in acidic conditions and are adapted to release an active (e.g., acid-labile} triazabutadiene molecule upon appropriate conditions, and methods for producing and using said protected or releasable triazabutadiene molecules (and products of cleavage).

Water-soluble triazabutadiene molecules and methods for producing and using such compounds. The triazabutadiene molecules may be more labile at pH levels below physiological pH, such as pH 7, pH 6, pH 5, etc. The triazabutadiene molecules and compounds may be used for depositing diazonium salt and/or cargo in a pH-sensitive manner. The triazabutadiene molecules may alternatively be cleaved in reducing conditions or as a light-catalyzed reaction. The compounds herein may be used for delivery of drugs, as part of detection systems, or for other applications such as underwater adhesive applications.

Water-soluble triazabutadiene molecules and methods for producing and using such compounds. The triazabutadiene molecules may be more labile at pH levels below physiological pH, such as pH 7, pH 6, pH 5, etc. The triazabutadiene molecules and compounds may be used for depositing diazonium salt and/or cargo in a pH-sensitive manner. The triazabutadiene molecules may alternatively be cleaved in reducing conditions or as a light-catalyzed reaction. The compounds herein may be used for delivery of drugs, as part of detection systems, or for other applications such as underwater adhesive applications.

Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II)

##STR00001##

wherein X, X.sub.1, X.sub.2, X.sub.3, X.sub.4 and X.sub.5, R.sub.1 through R.sub.4 and R.sub.9 are as described.

The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer (such as a cancer characterized by low levels of LMNA expression).

The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer (such as a cancer characterized by low levels of LMNA expression).